-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, K7Qw9cQG/H0rZA8M+62qlWbz+ntopQjD395hA1dU/To8mKDl0sHq6q4+wXtyg012 Yohmbc2n8Jcotvrm6YqshA== 0001181431-04-010189.txt : 20040217 0001181431-04-010189.hdr.sgml : 20040216 20040217175857 ACCESSION NUMBER: 0001181431-04-010189 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20040207 FILED AS OF DATE: 20040217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LOUCKS VERNON R JR CENTRAL INDEX KEY: 0001183294 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-10824 FILM NUMBER: 04610820 BUSINESS ADDRESS: STREET 1: THE AETHENA GROUP, LLC STREET 2: 1101 SKOKIE BLVD., STE. 240 CITY: NORTHBROOK STATE: IL ZIP: 60062 BUSINESS PHONE: 8479483600 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENOME THERAPEUTICS CORP CENTRAL INDEX KEY: 0000356830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 042297484 STATE OF INCORPORATION: MA FISCAL YEAR END: 0831 BUSINESS ADDRESS: STREET 1: 1OO BEAVER ST CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7813982300 MAIL ADDRESS: STREET 1: 100 BEAVER STREET CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: COLLABORATIVE RESEARCH INC DATE OF NAME CHANGE: 19920703 3 1 rrd33362.xml X0201 3 2004-02-07 0 0000356830 GENOME THERAPEUTICS CORP GENE 0001183294 LOUCKS VERNON R JR 100 BEAVER STREET WALTHAM MA 02453 1 0 0 0 Common Shares 233264 D Manny J. Bougoulas, Corporate Controller, by Power of Atty 2004-02-16 EX-24. 3 rrd25042_28676.htm POWER OF ATTORNEY rrd25042_28676.html
POWER OF ATTORNEY

      I hereby constitute and appoint each of Manny Bougoulas and Edy Mahoney,
signing singly, my true and lawful attorney-in-fact to:


(1) execute for and on my behalf, in my capacity as an officer and/or director
of Genome Therapeutics Corporation (the "Company"), Forms 3, 4 and 5 in
accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder;


(2) do and perform any and all acts for and on my behalf that may be necessary
or desirable to complete and execute any such Form 3, 4 or 5 and timely file
such form with the United States Securities and Exchange Commission and any
stock exchange or similar authority; and


(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be to my benefit,
in my best interest, or that I am legally required to do, it being understood
that the documents executed by such attorney-in-fact's discretion.


      I hereby grant to each such attorney-in-fact full power and authority to
do and perform any and every act and thing whatsoever requisite, necessary, or
proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as I might or could do if
personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact, or such attorney-in-
fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted. I
acknowledge that the attorneys-in-fact, in serving in such capacity at my
request, are not assuming, nor is the Company assuming, any of my
responsibilities to comply with Section 16 of the Securities Exchange Act of
1934.


        This Power of Attorn ey shall remain in full force and effect until I am no
longer required to file Forms 3, 4 and 5 with respect to my holdings of and
transactions in Company securities, unless I earlier revoke it in a signed
writing delivered to the attorneys-in-fact.


        IN WITNESS WHEREOF, I have caused this Power of Attorney to be executed as
of this 3rd day of February 2004.

                                                        /s/ Vernon R. Loucks
                                                         __________________
                                                        Vernon R. Loucks
                                                Director, Genome Therapeutics Corp.

-----END PRIVACY-ENHANCED MESSAGE-----